|
Letters

Online Drug Sales Quality, Safety,
Privacy
Letters
| Press
| Links
Letters
March
2, 1999
The Honorable
David M. Walker Comptroller General of the United States U.S.
General Accounting Office 441 G Street, N.W. Washington, D.C.
20548
Dear Mr.
Walker:
During the past
several years, Internet use has evolved dramatically from a tool
used mainly by research centers and universities to a powerful means
of moving commerce available to millions of households. American
consumers now use the Internet to purchase everything from airline
tickets to investments to almost any item traditionally sold in a
store.
One group of
goods increasingly sold this way are pharmaceuticals. Companies
reportedly selling pharmaceuticals online include "Thepillbox.com,"
"Drugstore.com," "Soma.com." and "PlanetRX.com." Ranging from both
over-the-counter health aids to actual prescription drugs, many of
these online pharmacy websites (also called "cybermedicine") now
allow consumers using a home computer to purchase a range of
pharmaceutical products once only available through a face-to-face
visit with a doctor and a pharmacist. According to some press
accounts, some Internet websites may even allow for a "virtual"
doctor visit: medical information is submitted to a web-based
drugstore, an online doctor reviews it and, based on that
information decides whether to send a prescription directly to a
customer=s residence. This suggests that some web-based companies
may be processing and delivering prescriptions for patients they
have never seen, a medical practice some view as highly unethical
and prone to serious problems.
A host of
serious regulatory concerns are indeed raised by online pharmacies.
For example, as patients are often required to submit highly
sensitive and personal medical data to the online prescription
company before their prescriptions are filled (or processed), it is
unclear how effective each online company=s methods are for
safeguarding such information. Unlike losing a credit card number to
an unscrupulous actor, misdirected or stolen personal medical
information could have very serious long-term consequences for the
consumer.
Others have
suggested that online pharmacies could contribute to the problem of
drug interactions, as the traditional face-to-face doctor-patient
relationship is replaced by an online computer transaction. Although
it appears that some online pharmacies require customers to fill out
forms listing what other medications they are taking, or what other
medical conditions they have, it is not clear that all firms require
this, or how such a check of this information will ultimately be
conducted. Finally, it remains murky how online pharmacies will
process (if at all) controlled substances, and not be susceptible to
abuse by hackers or other criminal elements. For example, if, as
reported, some Internet pharmacies provide prescription drugs
without requiring a patient to actually visit a doctor or
pharmacist, certain controlled substances could be seriously
susceptible to abuse.
In sum, we are
concerned that the rapidly exploding trend of online pharmacies may
be outpacing formal state and federal controls, and thus raising a
host of serious issues. Given our concerns, we are requesting that
the General Accounting Office (GAO) conduct a formal review of this
area to determine the following:
(1) How
pervasive is the online pharmaceutical industry? Please determine
roughly how many online operations now exist, trends for this
industry, and the dollar value in sales presently being conducted by
online pharmacies.
(2) Please
determine the differences between online pharmacies that presently
operate over the Internet. For example, some reports suggest that
most online pharmacies only fill prescriptions. Other reports,
however, have suggested that some actually provide for a doctor
consultation (for example, a quick questionnaire is submitted over
the Internet, the doctor reviews it, and then the prescription can
be approved and sent directly to the patient without a doctor ever
seeing the patient). How prevalent is this latter operation? Do any
trends appear in comparing one form of online pharmacy operation
with another?
(3) Please
determine how these firms are or are not being regulated by state
and federal agencies. First, who are the primary regulators of
online pharmacies at both the federal and state level? What are each
of their responsibilities relative to online pharmacies? Are there
serious jurisdictional gaps? If so, what are they, and what are
their implications for the consumer? Second, what are existing
regulators presently doing to oversee existing online pharmacies?
What concerns have been reported? What issues do regulators see
these firms as posing? As an example, can medical information be
sold by one online pharmacy company to another? Third, do existing
laws and regulations adequately apply to online pharmacy operations?
If not, what are the discrepancies, and what changes, if any, may
need to be made?
(4) How do these
firms deal with issues such as medical records privacy/protection,
the selling of controlled substances, or drug interactions? How
serious are these issues and what shortcomings, if any, do online
pharmacies have with regards to these issues? Also, how do online
pharmacies prevent unqualified persons from receiving prescriptions?
Are online pharmacies more susceptible to fraud or deception? If so,
please explain how?
(5) What quality
issues pertain to the methods used to ship these online
pharmaceutical products? Do their actual sources need to be
considered by state and federal regulators? If so, what are they and
what are their implications for the consumer? Does the existing
regulatory structure make it more difficult to guarantee quality,
safety, and effectiveness? If not, why?
Thank you for
your cooperation and attention to our request. If you have any
additional questions about this matter, please have your staff
contact Mr. Christopher Knauer of the Minority staff at (202)
226-3400. We look forward to working with you on this and other
important pharmaceutical integrity and consumer protection
issues.
Sincerely,
JOHN D.
DINGELL RANKING MEMBER COMMITTEE ON COMMERCE
RON
KLINK RANKING MEMBER SUBCOMMITTEE ON OVERSIGHT AND
INVESTIGATIONS
HENRY A.
WAXMAN MEMBER COMMITTEE ON COMMERCE
SHERROD
BROWN RANKING MEMBER SUBCOMMITTEE ON HEALTH AND
ENVIRONMENT

|